Eurofarma Sustainability Profile
Eurofarma, officially known as Eurofarma Laboratórios S.A., is a prominent Brazilian pharmaceutical company headquartered in São Paulo, Brazil. Established in 1972, Eurofarma has grown to become a key player in the Latin American pharmaceutical industry, with a strong presence across various operational regions, including Central and South America. Specialising in the development, manufacturing, and marketing of prescription medicines, generics, and over-the-counter products, Eurofarma is recognised for its commitment to quality and innovation. The company’s diverse portfolio includes therapeutic areas such as oncology, cardiology, and central nervous system disorders, setting it apart with its focus on patient-centric solutions. With a robust market position, Eurofarma has achieved significant milestones, including numerous certifications and awards for excellence in pharmaceutical practices, reinforcing its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Eurofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofarma's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eurofarma's reported carbon emissions
In 2024, Eurofarma reported total carbon emissions of approximately 50,093,000 kg CO2e. This figure includes Scope 1 emissions of about 21,450,000 kg CO2e, which arise from direct operations, and Scope 2 emissions of around 4,340,000 kg CO2e, related to purchased electricity. Additionally, Scope 3 emissions, which encompass indirect emissions from the value chain, totalled approximately 24,303,000 kg CO2e. Comparatively, in 2023, Eurofarma's total emissions were about 41,604,000 kg CO2e, with Scope 1 at approximately 16,992,000 kg CO2e, Scope 2 at around 7,827,000 kg CO2e, and Scope 3 at about 16,785,000 kg CO2e. This indicates a significant increase in emissions from 2023 to 2024. Over the past few years, Eurofarma has demonstrated a commitment to sustainability, although specific reduction targets or initiatives have not been disclosed. The company has not reported any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges. The emissions data is sourced directly from Eurofarma Laboratórios S.A., and no data has been cascaded from a parent or related organization. Eurofarma's emissions reporting includes all three scopes, reflecting a comprehensive approach to understanding and managing their carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 12,594,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,611,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Eurofarma's Industry?
How Carbon Intensive is Eurofarma's Location?
Eurofarma's Scope 3 Categories Breakdown
Eurofarma's Scope 3 emissions, which increased by 45% last year and increased by approximately 295% since 2019, demonstrating supply chain emissions tracking. A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 49% of total emissions under the GHG Protocol, with "Fuel and Energy Related Activities" being the largest emissions source at 32% of Scope 3 emissions.
Top Scope 3 Categories
Eurofarma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eurofarma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
